{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Fluctuations
Crinetics Pharmaceuticals, Inc. has experienced significant stock price fluctuations, currently at $44.34. The company has shown notable volatility over the past year, with a 52-week high of $62.53 and a low of $24.10. Its recent performance has outpaced the S&P 500 in the short term, while year-to-date returns reflect underperformance.
Is Crinetics Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Crinetics Pharmaceuticals, Inc. shows a mildly bullish trend with a bullish weekly MACD and moving averages, despite underperforming the S&P 500 year-to-date and over the past year, while significantly outperforming it over the last three years.
Is Crinetics Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Crinetics Pharmaceuticals, Inc. shows a mildly bullish trend due to positive daily moving averages and a bullish weekly MACD, despite mixed signals from longer-term indicators.
Is Crinetics Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Crinetics Pharmaceuticals, Inc. shows a mildly bullish trend due to positive daily moving averages and a bullish weekly MACD, despite mixed signals from monthly indicators and underperformance compared to the S&P 500.
Crinetics Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout
Crinetics Pharmaceuticals has recently achieved a Golden Cross, indicating a potential shift in momentum. While current indicators show bullish trends, mixed signals appear in longer-term metrics. Despite a one-year decline, the company has seen a notable three-year performance increase, drawing investor interest amid industry trends.
Crinetics Pharmaceuticals Hits Day High with 16.05% Surge in Stock Price
Crinetics Pharmaceuticals, Inc. has seen a notable increase in stock performance, achieving significant gains recently. Despite this short-term success, the company has struggled with negative results over the past 25 quarters and a substantial decline in operating profit over the last five years, alongside a market capitalization of USD 3,309 million.
Crinetics Pharmaceuticals Opens with 14.43% Gain, Surpassing S&P 500's 0.59% Rise
Crinetics Pharmaceuticals, Inc. has experienced a significant stock surge, with notable increases over the past day and month, outpacing the S&P 500. However, the company faces ongoing financial challenges, including negative operating profit growth and consecutive quarterly losses, indicating a complex financial situation despite recent performance gains.
Crinetics Pharmaceuticals Hits Day High with 27.92% Surge in Stock Price
Crinetics Pharmaceuticals, Inc. has seen notable trading activity, with a significant intraday high reached recently. The company has shown impressive short-term gains, outperforming the S&P 500, but faces longer-term challenges, including negative cash flow and a history of quarterly losses, with a market capitalization of USD 3,309 million.
Is Crinetics Pharmaceuticals, Inc. technically bullish or bearish?
As of August 15, 2025, Crinetics Pharmaceuticals, Inc. shows a mildly bearish technical trend with mixed signals across various time frames, having outperformed the S&P 500 recently but with significant negative returns year-to-date and over the past year.
Is Crinetics Pharmaceuticals, Inc. overvalued or undervalued?
As of August 7, 2025, Crinetics Pharmaceuticals, Inc. is considered risky and overvalued, with a Price to Book Value of 2.47, a negative EV to EBITDA of -4.88, and a year-to-date return of -30.61%, significantly underperforming compared to its peers and the S&P 500.
Is Crinetics Pharmaceuticals, Inc. overvalued or undervalued?
As of February 28, 2023, Crinetics Pharmaceuticals is considered overvalued with significant financial concerns, reflected in its negative earnings, a Price to Book Value of 2.47, an EV to EBITDA ratio of -4.88, and a year-to-date stock return of -41.50%, contrasting sharply with its peers and the S&P 500.
Is Crinetics Pharmaceuticals, Inc. technically bullish or bearish?
As of June 2, 2025, the market trend is mildly bearish, supported by daily moving averages and weekly Bollinger Bands, despite some mixed signals from the MACD and neutral indicators like RSI and OBV.
Who are in the management team of Crinetics Pharmaceuticals, Inc.?
As of March 2022, Crinetics Pharmaceuticals, Inc.'s management team includes Dr. R. Scott Struthers as CEO, along with several independent directors, including Dr. Wendall Wierenga as Chairman.
What does Crinetics Pharmaceuticals, Inc. do?
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing treatments for specialty endocrine diseases and related tumors. As of March 2025, it has a market cap of approximately $2.89 billion, with no net sales and a net loss of $97 million.
How big is Crinetics Pharmaceuticals, Inc.?
As of Jun 18, Crinetics Pharmaceuticals, Inc. has a market capitalization of $2.89 billion, with net sales of $0.36 million and a net profit of -$328.25 million over the latest four quarters. The company reported shareholder's funds of $1.32 billion and total assets of $1.73 billion as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
